Personalized genomic medicine: is a cancer care revolution achievable?

2011 ◽  
pp. 2-6
Author(s):  
Dimitrios H Roukos
Keyword(s):  
Cancer Care ◽  
Genomic Medicine

scholarly journals Building a Personalized Medicine Infrastructure at a Major Cancer Center

2013 ◽  
Vol 31 (15) ◽  
pp. 1849-1857 ◽  
Author(s):  
Funda Meric-Bernstam ◽  
Carol Farhangfar ◽  
John Mendelsohn ◽  
Gordon B. Mills
Keyword(s):  
Cancer Therapy ◽  
Cancer Care ◽  
Cancer Biology ◽  
Genomic Medicine ◽  
Cancer Center ◽  
Molecular Therapeutics ◽  
Number Of Patients ◽  
Wide Range ◽  
Personalized Cancer Therapy ◽  
Personalized Cancer

Our understanding of cancer biology is rapidly increasing, as is the availability and affordability of high throughput technologies for comprehensive molecular characterization of tumors and the individual's own genetic makeup. Thus, the time is right to implement personalized molecular medicine for all patients with cancer. Personalized approaches span the full cancer care spectrum from risk stratification to prevention, screening, therapy, and survivorship programs. Several molecular therapeutics have entered clinical trials creating a huge opportunity to couple genomic markers with this emerging drug tool kit. The number of patients managed in major cancer centers creates a challenge to the implementation of genomic technologies required to successfully deliver on the promise of personalized cancer care. This requires a major investment in infrastructure to facilitate rapid deployment of multiplex, cost-effective, and tissue-sparing assays relevant across multiple tumor lineages in the Clinical Laboratory Improvement Amendments (CLIA) environment. Efforts must be made to ensure that assays are accessible to patients most likely to be enrolled onto molecular-marker–driven trials and that the tests are billable and payable, which will make them accessible to a wide range of patients. As the number of patients and aberrations increase, it will become critical to provide decision support for genomic medicine. Institutional commitment is needed to optimize accessibility and quality of research biopsies and to facilitate novel personalized cancer therapy trials. This article will focus on the challenges and opportunities that accompany the building of infrastructure for personalized cancer therapy.

scholarly journals The Role of Decision Impact Studies in Genomic Medicine in Cancer Care: A Scoping Review and Bibliometric Analysis Protocol

2021 ◽  
Author(s):  
Gillian Parker ◽  
Fiona A Miller
Keyword(s):  
Decision Making ◽  
Clinical Practice ◽  
Bibliometric Analysis ◽  
Scoping Review ◽  
Cancer Care ◽  
Clinical Decision Making ◽  
Genomic Medicine ◽  
Impact Studies ◽  
The Impact

Abstract BackgroundDecision impact studies have become increasingly prevalent in oncology in recent years, particularly in breast cancer prognostic research. Such studies, which aim to evaluate the impact of a test on clinical decision-making, appear to be a new form of knowledge with the potential to impact clinical practice and regulatory decision-making in genomic medicine. Yet their origins, intended purpose and usage have not yet been explored. The objectives of this review are to identify and characterize decision impact studies in genomic medicine in cancer care. This review is comprised of two parts. First, we will conduct a scoping review to catalogue the characteristics of decision impact studies. The scoping review will be followed by a bibliometric analysis to understand the role of actors and institutions in the production and dissemination of this new knowledge, by identifying influential articles, authors, global research trends and collaboration networks. MethodsWe will conduct a scoping review and a bibliometric analysis of the scoping review results. The search will include four databases, Medline, Embase, Scopus and Web of Science, using a comprehensive search strategy developed through a preliminary review of the literature. Arksey & O’Malley’s scoping review methodology, with updates by Levac et al. will be used, and the review will be reported following the PRISMA-ScR checklist. The FT Model will be used to collect and analyze data on clinical utility of decision impact studies. Our bibliometric analysis, using Bibliometrix software, will elucidate the evolution of these studies and provide data on the trends, influences and networks emerging in the field.DiscussionThis review will be a first step in understanding the evolution and uses of these studies and their potential influence on the integration of emerging genomic technologies into clinical practice. By exploring their origin and evolution across space and time, this study will equip future research to investigate the role of these studies in decision-making for regulatory processes, including market access and public and private coverage decision-making. Systematic review registration: Open Science Framework osf.io/hm3jr

scholarly journals Personalized Cancer Care: Risk Prediction, Early Diagnosis, Progression, and Therapy

2016 ◽  
Vol 1 (3) ◽  
pp. 1-9
Author(s):  
Kurt S. Zänker ◽  
Anne-Lise Borresen-Dale ◽  
Hans-Peter Huber
Keyword(s):  
Risk Prediction ◽  
Cancer Care ◽  
Tumor Therapy ◽  
Genomic Medicine ◽  
Tumor Evolution ◽  
Genetic Profiling ◽  
Intracellular Proteins ◽  
Precise Diagnosis ◽  
Methods Analytical ◽  
Personalized Cancer

At the annual prestigious International Symposium of the Fritz-Bender Foundation, Munich, 18-20 May, 2016, researchers, clinicians, and students discussed the state of the art and future perspectives of genomic medicine in cancer. Genomic medicine (also known as precision medicine/oncology) should help clinicians to provide a more precise diagnosis and therapy in oncology for individual patients. The meeting focused on next-generation sequencing methods, analytical computational analysis of big data, and data mining on the way to translational and evidence-based medicine. The meeting covered the social and ethical impact of genomic medicine as well as news and views on antibody targeting of intracellular proteins, on the architecture of intracellular proteins and their impact on carcinogenesis, and on the adaptation of tumor therapy in due consideration of tumor evolution. Subheadings like “Genetic Profiling of Patients and Risk Prediction,” “Molecular Profiling of Tumors and Metastases,” “Tumor-Host Microenvironment Interaction and Metabolism,” and “Targeted Therapy” were subsumed under the main heading of “Personalized Cancer Care.”

scholarly journals Horizon Scanning in Cancer Genomics: How Advances in Genomic Medicine Will Change Cancer Care Over the Next Decade

2021 ◽  
Author(s):  
Lydia M. Seed
Keyword(s):  
Patient Care ◽  
Cancer Patients ◽  
Cancer Care ◽  
Cancer Genomics ◽  
Care Pathway ◽  
Genomic Medicine ◽  
Survival Rates ◽  
Precision Oncology ◽  
Clinical Environment ◽  
Horizon Scanning

Abstract Purpose of Review Advances in genomic medicine have the potential to revolutionise cancer patient care by driving forwards the clinical practice of precision oncology. This review aims to outline how genomic medicine advances may alter the care of cancer patients and their families over the next 10 years. Recent Findings The translation of oncogenomic advances into the clinical environment will likely be facilitated by the increasing availability of next-generation sequencing technologies and the increasing genomic literacy of healthcare professionals. The implementation of the centralised, nationwide NHS Genomic Medicine Service promises to improve equity of cancer care and to facilitate personalisation of almost every stage of the care pathway, from informing population screening and how we diagnose cancer to delivering prognoses and surveillance. Advances in cancer pharmacogenomics, and other “omics” technologies, have a tremendous potential to optimise patient care. Genomic medicine advances will also enhance the care offered to cancer patients’ families. Summary Genomic medicine advances are likely to transform almost every aspect of a cancer patient’s care pathway. Cancer care will profoundly improve over the next decade, increasing UK cancer survival rates and improving patient outcomes.

Cancer support nurses: a co-ordinating role in cancer care

1998 ◽  
Vol 7 (2) ◽  
pp. 125-128 ◽  
Author(s):  
McILLMURRAY ◽  
CUMMINGS ◽  
HOPKINS ◽  
McCANN
Keyword(s):  
Cancer Care ◽  
Cancer Support

199: Correlates of Access to Prostate Cancer Care in a Statewide Public Assistance Program

2007 ◽  
Vol 177 (4S) ◽  
pp. 67-67
Author(s):  
David C. Miller ◽  
Laura Baybridge ◽  
Lorna C. Kwan ◽  
Ronald Andersen ◽  
Lillian Gelberg ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Care ◽  
Public Assistance ◽  
Assistance Program

205: Variations in Prostate Cancer Care According to Race, Geographic Region, and Literacy: Initial Findings from the Compare Registry

2006 ◽  
Vol 175 (4S) ◽  
pp. 66-67
Author(s):  
Charles L. Bennett ◽  
Oliver Sartor ◽  
Susan Halabi ◽  
Michael W. Kattan ◽  
Peter T. Scardino
Keyword(s):  
Prostate Cancer ◽  
Cancer Care ◽  
Geographic Region
Sign in / Sign up

Export Citation Format

Share Document